Cellectar Biosciences Partners with NorthStar for Ac-225 Supply

Cellectar Biosciences Forms Strategic Alliance with NorthStar

NorthStar will deliver non-carrier-added Ac-225 for cancer treatment programs

Cellectar Biosciences, Inc. (NASDAQ: CLRB), a dedicated clinical biopharmaceutical enterprise concentrated on innovating cancer therapies, has entered a pivotal supply agreement with NorthStar Medical Radioisotopes, LLC. This collaboration aims to secure NorthStar's non-carrier added (n.c.a.) Actinium-225 (Ac-225) as part of enhancing their clinical program offerings. The CLR 121225 initiative, integrating the unique Phospholipid Ether (PLE) delivery system with Ac-225, targets solid tumor treatment.

The current landscape of medical radioisotope supply chains often encounters challenges that can compromise patient care, clinical trials, and drug development operations. With Ac-225 recognized as a scarce radioisotope, its limited availability poses obstacles for both clinical advancement and market commercialization.

James Caruso, president and CEO of Cellectar, expressed his enthusiasm regarding the PLE platform, stating, “It uniquely optimizes the delivery of any radioisotope tailored for specific tumor types. The CLR 121225 program, which utilizes Ac-225, has shown encouraging preclinical findings in targeting pancreatic, triple-negative breast, and other solid tumors, warranting its advancement to clinical trials.” Cellectar plans to initiate human clinical trials for CLR 121225 in 2025, reinforcing their stage in pioneering cutting-edge radiotherapeutics with this strategic agreement that assures a steady supply of Ac-225, vital for their clinical development pathway.

NorthStar stands at the forefront of innovation within the radiopharmaceutical field, consistently developing and producing high-purity radioisotopes. Frank Scholz, NorthStar's president and CEO, highlighted the growing interest around alpha-emitting therapies. He remarked, “While the demand has surged for therapies like CLR 121225, supply issues with Ac-225 have hindered progress. Our commitment lies in minimizing technological and operational hurdles, ensuring reliable access to eco-friendly, high-grade Ac-225 to facilitate the realization of these novel therapies.”

The partnership encompasses a decade-long agreement for the supply of Ac-225, with activities projected to commence in 2025.

CLR 121225 is still under investigation and awaits regulatory approval.

About NorthStar Medical Radioisotopes

NorthStar is a trailblazing commercial-stage radiopharmaceutical firm dedicated to enhancing patient care through innovative technologies that enable large-scale production of essential radioisotopes. These radioisotopes can be linked to various molecules, empowering them to visualize and treat cancers and other severe conditions effectively. NorthStar’s exceptional standing in the radiopharmaceutical sector is bolstered by its proprietary production methodologies, robust management, and eco-conscious technologies. The company not only produces copper-67 (Cu-67) but is also poised to lead the market in non-carrier-added Ac-225 production.

NorthStar Services

The company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) provides specialized services designed to propel biopharmaceutical companies forward in their development and commercialization endeavors.

About Cellectar Biosciences

Cellectar Biosciences is a prominent late-stage clinical biopharmaceutical entity that concentrates on discovering and commercializing innovative cancer treatments, through both independent efforts and collaborative research endeavors. Their strategic focus revolves around harnessing the proprietary Phospholipid Drug Conjugate™ (PDC) platform. This cutting-edge system aims to develop next-generation solutions targeting cancer cells, increasing efficacy while minimizing unintended side effects.

Cellectar's Product Pipeline

Among their notable products, iopofosine I 131, a small-molecule PDC aimed at delivering a targeted iodine-131 (radioisotope) therapy, showcases Cellectar's commitment to innovation. Complementing this are a series of proprietary preclinical PDC chemotherapy programs and multiple partnered PDC projects.

Frequently Asked Questions

What is the focus of Cellectar Biosciences?

Cellectar Biosciences specializes in discovering and developing innovative drugs specifically for cancer treatment.

What radioisotope is involved in the Cellectar and NorthStar partnership?

The partnership primarily focuses on the supply of Actinium-225 (Ac-225).

How long is the partnership agreement between Cellectar and NorthStar?

The agreement is set for ten years, beginning operations in 2025.

What does the CLR 121225 program aim to achieve?

The CLR 121225 program aims to treat solid tumors using a proprietary delivery platform combined with Ac-225.

Is CLR 121225 approved for clinical use?

No, CLR 121225 is still in the investigational stage and has not yet received regulatory approval.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.